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 INTRODUCTION 
 Global measures of cognitive functioning are important in 
both the clinical and research settings. They allow clinicians 
to effi ciently gauge a patient’s overall level of functioning, 
and to communicate this information to other clinicians. In 
research studies, global measures of cognitive status provide 
investigators and readers a practical yardstick with which to 
judge participants’ disease severity. Global measures are 
particularly useful in cross-sectional and longitudinal inter-
vention studies, where complex patterns of performance on 
different cognitive subtests and across individuals, and vari-
able rates of changes on different cognitive subtests and 
across individuals, would otherwise be diffi cult to assess, 
scrutinize, and communicate. Thus, although global perfor-
mance measures are necessarily associated with a loss of 
information which would be unacceptable in the diagnostic 
and differential diagnostic process, they represent an elegant 
solution to a variety of practical issues in the clinical and 
research environment. 
 Pharmacologic and non-pharmacologic intervention 
studies have, therefore, used simple and simplifying measures 
of global functioning to judge cognitive performance at 
baseline and over time. These include in particular the Mini-
Mental State Examination (MMSE; Folstein, Folstein, & 
McHugh,  1975 ), the Alzheimer Disease Assessment Scale 
(ADAS-Cog; Rosen, Mohs, & Davis,  1984 ), and for se-
verely impaired individuals the Severe Impairment Battery 
(SIB; Panisset, Roundier, Saxton, & Boller,  1994 ). The 
Consortium to Establish a Registry on Alzheimer’s Disease-
Neuropsychological Assessment Battery (CERAD-NAB; 
Morris, Mohs, Rogers, Fillenbaum, & Heyman,  1988 ; Welsh 
et al.,  1994 ) may provide the basis for an alternative global 
assessment measure. The CERAD-NAB has proven useful 
for the diagnosis of Alzheimer’s disease (AD), and a validated 
and normed version of this test battery has been established 
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 Abstract 
 The goal of the present study was to evaluate the diagnostic discriminability of three different global scores for the 
German version of the Consortium to Establish a Registry on Alzheimer’s Disease-Neuropsychological Assessment 
Battery (CERAD-NAB). The CERAD-NAB was administered to 1100 healthy control participants [NC; Mini-Mental 
State Examination (MMSE) mean = 28.9] and 352 patients with very mild Alzheimer’s disease (AD; MMSE 
mean = 26.1) at baseline and subsets of participants at follow-up an average of 2.4 (NC) and 1.2 (AD) years later. 
We calculated the following global scores: Chandler et al.’s (2005) score (summed raw scores), logistic regression on 
principal components analysis scores (PCA-LR), and logistic regression on demographically corrected CERAD-NAB 
variables (LR). Correct classifi cation rates (CCR) were compared with areas under the receiver operating characteristics 
curves (AUC). The CCR of the LR score (AUC = .976) exceeded that of the PCA-LR, while the PCA-LR (AUC = .968) 
and Chandler (AUC = .968) scores performed comparably. Retest data improved the CCR of the PCA-LR and Chandler 
(trend) scores. Thus, for the German CERAD-NAB, Chandler et al.’s total score provided an effective global measure 
of cognitive functioning, whereby the inclusion of retest data tended to improve correct classifi cation of individual 
cases. ( JINS , 2010,  16 , 910– 920 .) 
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in German-speaking Europe as a minimal common screening 
battery for dementia syndromes (German version of the 
CERAD-NAB; available at Memory Clinic, Basel, Switzer-
land,  http :// www . memoryclinic . ch ; Aebi,  2002 ; Thalmann 
et al.,  2000 ). The CERAD has also proven sensitive to cogni-
tive impairments occurring in the early stages of dementia 
and to cognitive changes over long time spans (Fillenbaum, 
Unverzagt, Ganguli, Welsh-Bohmer, & Heyman,  2002 ; Morris 
et al.,  1989 ,  1993 ; Welsh, Butters, Hughes, Mohs, & Heyman, 
 1991 ,  1992 ; Zehnder, Bläsi, Berres, Spiegel, & Monsch,  2007 ). 
 Chandler et al. ( 2005 ) recently developed a total score for 
the American version of the CERAD-NAB. This total score 
was created by summing six CERAD subtest scores (ex-
cluding MMSE and praxis recall; maximum score = 100) 
and submitting the sum to a regression analysis to correct for 
demographic status. They provide normative data ( T -scores) 
for these demographically corrected CERAD-NAB total 
scores. Thus, this score has the advantage that it is easy to 
calculate and characterizes global cognitive performance 
within the patient’s demographic framework. As expected, 
this score discriminated normal control participants (NC) 
from patients with probable AD signifi cantly better than the 
MMSE (Chandler et al.,  2005 ). However, it is unclear 
whether the simple sum of CERAD-NAB variables provides 
the most powerful diagnostic discrimination between NC 
and AD. Moreover, it remains to be established whether 
Chandler et al.’s and other potential composite scores of 
CERAD-NAB performance retain their discriminatory 
power with AD individuals in very early stages of dementia 
as well during longitudinal assessment. 
 The goals of the present study were, therefore, to (1) deter-
mine the discriminatory utility of Chandler et al.’s total score 
of German CERAD-NAB performance with groups of NC 
participants and AD patients in very mild stages of the disease 
(MMSE in both groups  ≥ 24/30), (2) determine the relative 
diagnostic discriminabilities of three different global CERAD-
NAB scores with groups of NC individuals and AD patients, 
(3) to determine and compare the longitudinal discriminatory 
power of the different global CERAD-NAB scores, and (4) 
examine whether a combination of cross-sectional and longi-
tudinal scores improves diagnostic classifi cation. 
 MATERIALS AND METHODS 
 Healthy Aged Participants 
 A total of 1,100 healthy aged individuals (NC) participated 
(see  Table 1 ). These individuals were a subset of BASEL 
study participants (Basel Study on the Elderly; Monsch 
et al.,  2000 ) and formed the normative sample for the German 
version of the CERAD-NAB. Baseline testing took place be-
tween 1997 and 2001. Additional neuropsychological tests 
included the following: Trail Making Test (Army Individual 
Test Battery,  1944 ), nonverbal and phonemic fl uency 
(Regard, Strauss, & Knapp,  1982 ; Thurstone,  1938 ), the 
modifi ed Wisconsin Card Sorting Test (Nelson,  1976 ), digit 
span and Corsi blocks (Härting, Markowitsch, Neufeld, 
Calabrese, Deisinger, & Kessler,  2000 ). All participants were 
thoroughly medically screened and fulfi lled the following 
inclusion criteria: German as fi rst language;  Z scores  ≤ −1.96 
(2.5th percentile) in no more than 1 of the 11 CERAD-NAB 
variables; and were in good health, that is, had no current 
systemic illnesses, no current depression according to the 
Diagnostic and Statistical Manual of Mental Disorders, 4th 
Edition [American Psychiatric Association (APA),  1994 ] as 
assessed with a standardized questionnaire (Kühner,  1997 ), 
no current diseases interfering with the administration of 
neuropsychological tests (e.g., severe hearing or visual defi -
cits), or diseases of the central nervous system (CNS) at the 
time of testing. Moreover, participants had no diseases or 
events during life that could have negatively impacted on 
CNS activity, and had never been hospitalized for a psychi-
atric illness. This project was approved by the local Ethics 
Committee, and written informed consent was obtained 
from all participants. 
 Due to resource limitations, only 549 participants were 
invited for follow-up circa 2 (T 2 ) and 4 (T 3 ) years after base-
line. T 2 data from participants who remained cognitively 
healthy at T 3 ( n = 524) were included in the longitudinal 
analyses [mean of 2.4 years ( SD = 0.3) following baseline]. 
 Table 2 lists differences between NC participants with and 
without follow-up at T 2 . The testing protocol at T 2 was iden-
tical to that at T 1 . 
 Table 1.  Characteristics of healthy aged participants (NC) and patients with probable Alzheimer`s disease (AD) in the 
cross-sectional sample (T 1 ) 
  NC  AD  Comparisons 
 N  1,100  352  
 Gender (male, female)  690, 410  149, 203  χ 2 = 45.5 * 
 Percentage male  62.7  55.7  
 Age ±  SD (y)  68.7 ± 7.8  75.7 ± 5.9  t = 17.9 * 
 min-max  49 – 92  56 – 89  
 Education ±  SD (y)  12.5 ± 3.0  11.7 ± 3.0  t = 4.2 * 
 min-max  7 – 20  7 – 20  
 MMSE ±  SD  28.9 ± 1.1  26.1 ± 1.6  t = 30.0 * 
 min-max  24 – 30  24 – 30  
 Note.   y = years. MMSE = Mini-Mental State Examination (Folstein et al.,  1975 ). * p < .001. 
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 AD Patients with Very Mild to Mild Dementia 
 A total of 352 patients from the Memory Clinic at the 
University Hospital Basel fulfi lled inclusion criteria for 
this study of (1) a diagnosis of probable AD according to 
the criteria outlined by the National Institute for Neuro-
logical and Communicative Disorders and Stroke and the 
Alzheimer`s Disease and Related Disorders Association 
(NINCDS-ADRDA; McKhann, Drachman, Folstein, 
Katzman, Price, & Stadlan,  1984 ) and DSM-IV (APA,  1994 ) 
and (2) an MMSE score  ≥ 24/30 (see  Table 1 ). The MMSE 
inclusion criterion ensured that patients were in the very 
early stages of the disease. All patients underwent a thor-
ough interdisciplinary examination including a comprehen-
sive neuropsychological assessment (same test battery as for 
NC sample), a medical examination including neurological 
status exam, structural brain imaging and laboratory tests 
(Monsch et al.,  1995 ). We note that, although diagnosing cli-
nicians were not provided with CERAD-NAB total scores, 
they were presented with individual CERAD-NAB subtest 
scores together with other neuropsychological test scores, all 
categorized by cognitive domain. Thus, NC-AD differences 
in CERAD total scores reported below are most likely artifi -
cially infl ated. We note that this artifi cial infl ation affects  all 
CERAD total scores. As such, the comparison of different 
CERAD total scores with one another—the primary goal of 
this study—is not confounded with the inclusion of CERAD 
data in the diagnostic process. Depressive symptoms were 
probed with the short version of the Geriatric Depression 
Scale (GDS; Sheikh & Yasavage,  1986 ). At T 1 , 85% of the AD 
patients had no depressive symptoms (GDS score 0–4), 11% 
had mild (GDS score 5–7), 3% moderate (GDS score 8–10), 
and 2% pronounced (GDS score > 11) depressive symptoms. 
 Forty-seven percent ( n = 165) of patients agreed to partic-
ipate at a follow-up assessment and were tested longitudi-
nally an average of 1.2 years ( SD = 0.3) after baseline. All 
patients retained their diagnosis of AD at follow-up, and all 
retested patient data were included in the longitudinal 
analyses (see  Table 2 ). The sample of AD patients not avail-
able for follow-up included more females and older, less well-
educated patients with lower MMSE scores (see  Table 2 ). 
At T 2 , 82% of the patients had no depressive symptoms, 
13% had mild, 5% moderate and less than 1% pronounced 
depressive symptomatology according to the GDS. In the 
interval between assessments (but not before baseline),  n = 
108 (65%) of the longitudinal patient group were treated 
with acetylcholine-esterase inhibitors only,  n = 6 (4%) took 
part in group memory training only (Ermini-Fünfschilling & 
Meier,  1995 ),  n = 21 (13%) patients received both forms of 
therapy, and  n = 30 (18%) patients received no specifi c 
dementia therapy. 
 Material 
 NC participants and AD patients were administered the 
German version of the CERAD-NAB (Thalmann et al.,  2000 ) 
by experienced neurospychologists or trained psychology 
students. This test battery is comprised of subtests designed 
to measure those cognitive functions typically affected by 
AD, that is: “animal fl uency” (60 s), a modifi ed version of 
the “Boston Naming Test” (BNT; maximum score = 15), the 
MMSE (maximum score = 30), “word list – total” (the sum 
of words learned after three trials of the 10-word learning 
list; maximum score = 30), “fi gures – copy” (maximum 
score = 11), “word list – delayed recall” (maximum score = 10), 
 Table 2.  Characteristics of healthy aged participants (NC) and patients with probable Alzheimer`s disease (AD) in the longitudinal 
subsample (T 1 and T 2 ; follow-up data) and those with no follow-up data 
 
 Follow-up data  No follow-up data 
 NC  AD  Comparisons  NC  AD  Comparisons 
 (A)  (B)  (A, B)  (C)  (D)  (A, C)  (B, D) 
 n  524  165   576  187   
 Gender (male, female)  291, 233  81, 84  χ 2 = 2.1  399, 177  68, 119  χ 2 = 22.1 **  χ 2 = 5.8 † 
 Percentage male  55.5  49.1   69.3  36.4   
 Age (T 1 ) ±  SD (y)  68.0 ± 7.7  74.8 ± 5.9  t = 12.0 **  69.4 ± 7.9  76.5 ± 5.7  t = 2.97 *  t = 2.78 * 
 min-max  49 – 88  56 – 87   49 – 92  60 – 89   
 Education ±  SD (y)  12.4 ± 2.9  12.1 ± 3.2  t = 1.0  12.5 ± 3.0  11.3 ± 2.9  t = 0.8  t = −2.4 † 
 min-max  7 – 20  7 – 20   8 – 20  7 – 20   
 MMSE (T 1 ) ±  SD  29.0 ± 1.1  26.4 ± 1.6  t = 18.7 **  28.8 ± 1.2  25.9 ± 1.5  t = −2.3 †  t = −3.1 * 
 min-max  24 – 30  24 – 30   24 – 30  24 – 30   
 MMSE (T 2 ) ±  SD  28.8 ± 1.2  24.5 ± 3.1  t = 17.7 **     
 min-max  23 – 30  15 – 30      
 MMSE (T 2 – T 1 ) ±  SD  −0.1 ± 1.3  −1.9 ± 2.7  t = 8.1 **     
 min-max  −6 – 4  −10 – 5      
 Test-Retest-Interval ±  SD (y)  2.36 ± 0.3  1.2 ± 0.3  t = 8.9 **     
 min-max  1.9 – 3.4  0.5 – 3.5      
 Note.   T 1 = Baseline; T 2 = Follow-up; y = years. MMSE = Mini-Mental State Examination (Folstein et al.,  1975 ). ** p < .001; * p < .01; † p < .05. 
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“word list – recognition” (maximum score = 100%), and 
“fi gures – delayed recall” (maximum score = 11). Three 
additional variables were created: the number of word 
responses given during the three word list learning trials and 
word list delayed recall that were not on the original list was 
conceptualized as “word list – intrusions”; the proportion of 
correctly recalled words during the verbal delayed recall com-
pared with verbal learning trial 3 was “word list – savings”; 
and similarly the proportion of correctly drawn fi gures during 
fi gural delayed free recall compared with the copy condition 
was “fi gures – savings”. A large, independent study with NC 
and AD patients demonstrated that these German CERAD-
NAB variables have good to excellent discriminative validity 
(Aebi,  2002 ). 
 Statistical Analyses 
 Global CERAD-NAB scores 
 Three different global CERAD-NAB scores (all excluding 
the MMSE) were calculated for the NC and AD participants 
in the cross-sectional sample at T 1 (cf.  Table 1 ), and for the 
NC and AD participants in the longitudinal sample at T 1 and 
T 2 (cf.  Table 2 ): Chandler’s total score, a new CERAD-NAB 
score derived from a principal components analysis of NC 
data and subsequent logistic regression (PCA-LR score), 
and a global score based on a logistic regression with jack-
knife procedure (LR score). The MMSE was not included in 
the global score calculation to more directly compare the 
performance of our total scores with that of Chandler et al. 
( 2005 ), and because MMSE scores were used as an inclusion 
criterion for AD patients to participate in this study. To com-
pare the abilities of each measure to discriminate between 
NC and AD participants, we produced receiver operating 
characteristics (ROC) curves for each global score and com-
pared the corresponding areas under the curves (see Hanley & 
McNeil,  1983 ). For descriptive purposes only, we also report 
the sensitivity, specifi city and correct classifi cation rate 
(CCR; mean of sensitivity and specifi city) of each score. 
 Chandler score 
 Chandler CERAD total score was calculated using a procedure 
identical to Chandler et al. ( 2005 ). Raw scores on six German 
CERAD-NAB variables (i.e., animal fl uency with a maximum 
score of 24 words; modifi ed BNT; word list – total; word list 
– delayed recall; word list – recognition, subtracting the 
number of false positives from the number of true positives; 
fi gures – copy) were summed, and an age, education and gen-
der corrected regression formula was created with a multiple 
regression analysis based on the present participants’ data. 
 Principal Components Analysis – Logistic Regression 
(PCA-LR) score 
 A principal components analysis (PCA) was conducted to re-
duce the CERAD-NAB variables to one score while accounting 
for intercorrelations between variables and minimizing redun-
dancies. CERAD-NAB variables were transformed to achieve 
normality of standardized residuals ( Z scores) in regression 
models adjusting for covariates (Berres, Zehnder, Bläsi, & 
Monsch,  2007 ). The  Z scores of the 10 CERAD-NAB variables 
of the NC group at T 1 , excluding MMSE, were used in the 
PCA. A three-factor PCA solution was selected because three 
factors achieved eigenvalues greater than 1. Three factor scores 
were calculated for each participant using coeffi cient values 
rounded to one decimal place. These three factor scores were 
submitted to a logistic regression analysis with backward elim-
ination to produce a global score. The global score was adjusted 
in a linear model with age, education, and the square of these 
variables. This analysis resulted in a  Z score which was then 
linearly transformed to a mean of 100 and  SD of 15. 
 The PCA-LR score was also calculated for each AD pa-
tient. The cutoff score for the PCA-LR scores was deter-
mined with a binary logistic regression analysis. A case was 
classifi ed as “demented” if the predicted probability for 
dementia was greater than the proportion of true AD patients 
in the sample. The cutoff value for the binary logistic regres-
sion analysis was, therefore, set to a probability of 0.25. 
 PCA-LR scores for T 2 CERAD-NAB performance were cal-
culated using a procedure identical to the one described above. 
 Logistic regression (LR) score 
 Stepwise logistic regression analyses with backward elimi-
nation (exclusion criterion:  p = .10; inclusion criterion:  p = .05; 
cutoff value = 0.25) comparing NC participants to AD pa-
tients were performed on all 10  z -transformed baseline 
CERAD-NAB scores (excluding MMSE). Logistic regres-
sion estimates the optimal weighting of each subtest score, 
as determined by the best fi t of predicted probabilities to ob-
served outcomes. Thus, it tends to give high weights to vari-
ables with high measurement precision, similar to methods 
which directly weight by precision (see, e.g., Wouters, van 
Gool, Schmand, & Lindeboomm,  2008 ), but has the added 
advantage of accounting for correlations between variables. 
 Cross-validation 
 To determine the diagnostic accuracies of each baseline 
CERAD-NAB total score, we fi rst randomly split the NC 
and AD baseline samples (group A and group B) for cross-
validation analyses (see  Table 3 for demographic informa-
tion). Thus, total scores were derived from group A and 
applied to group B, and in a second step, scores were derived 
from group B and applied to group A. The diagnostic dis-
criminability of each set of scores was quantifi ed with sensi-
tivity, specifi city, CCR, and AUC. 
 Entire Sample 
 To foreshadow the cross-validation results, each set of 
analyses resulted in comparable diagnostic discriminabilities 
(see  Table 4 ), indicating a high stability of the generated total 
scores. To produce a single set of total score formulae, we 
next calculated CERAD total scores on the entire participant 
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population. For the LR score based on the entire sample, the 
stability of the regression model was tested with a cross-
validation via a jackknife procedure (“leave one out” method). 
This procedure was used to calculate LR scores at T 1 and T 2 . 
We report the results (sensitivity, specifi city, CCR, AUC) of 
these analyses after the jackknife cross-validation. 
 Global Change Scores 
 To determine the extent to which the global scores discrimi-
nated between the longitudinal performance of NC and AD 
participants, difference scores were calculated by subtracting 
each score at T 1 from the corresponding score at T 2 . Because 
difference scores based on  Z scores are also infl uenced by 
demographic variables, difference scores were corrected for 
the effects of age, education, gender, baseline performance, 
and all possible interactions between these variables (Zehnder 
et al.,  2007 ). Forty-fi ve regression models were fi tted for each 
global score. The most accurate model, that is, the model with 
the smallest standard deviation of the predicted residuals, was 
selected based on the results of the Predicted Residual Sum of 
Squares statistics (Berres et al.,  2007 ). 
 Combination of Cross-sectional and Longitudinal 
Data 
 To determine whether the correct classifi cation rate based on 
combined information from (a) T 1 and T 2 and (b) T 1 and 
 Table 3.  Characteristics of healthy aged participants (NC) and patients with probable Alzheimer`s disease (AD), 
randomly assigned to groups A and B for cross-validation 
  Group A  Group B  Comparisons 
 NC 
  n  550  550  
  Gender (male, female)  342, 208  348, 202  χ 2 = .140 
  Percentage male  62.2  63.3  
  Age ±  SD (y)  68.5 ± 8.0  68.9 ± 7.7  t = -.747 
  Education ±  SD (y)  12.5 ± 3.1  12.4 ± 2.9  t = .580 
  MMSE ±  SD  28.9 ± 1.1  28.8 ± 1.2  t = .817 
 AD 
  n  176  176  
  Gender (male, female)  75, 101  74, 102  χ 2 = .012 
  Percentage male  42.6  42.0  
  Age ±  SD (y)  75.4 ± 6.0  76.0 ± 5.8  t = -.897 
  Education ±  SD (y)  11.6 ± 3.0  11.8 ± 3.2  t = -.645 
  MMSE ±  SD  26.2 ± 1.6  26.1 ± 1.6  t = .541 
 Note.  y = years. MMSE = Mini-Mental State Examination (Folstein et al.,  1975 ). 
 Table 4.  Results of the double cross-validation of randomly split groups 
 
 Training data  Validation data 
 Group A  Group B 
 Chandler score  PCA-LR score  LR score  Chandler score  PCA-LR score  LR score 
 Sensitivity  90.9  90.9  93.2  93.2  93.2  90.9 
 Specifi city  91.5  90.2  91.3  90.0  90.4  90.7 
 CCR  91.2  90.6  92.3  91.6  91.8  90.8 
 AUC  .967  .972  .980  .970  .968  .973 
  Group B  Group A 
 Chandler score  PCA-LR score  LR score  Chandler score  PCA-LR score  LR score 
 Sensitivity  91.5  92.0  92.0  88.6  89.8  88.6 
 Specifi city  91.3  90.5  92.4  92.9  90.4  92.7 
 CCR  91.4  91.3  92.2  90.8  90.1  90.7 
 AUC  .969  .966  .978  .965  .969  .972 
 Note.  PCA-LR = logistic regression on principal components analysis scores; LR = logistic regression on demographically corrected (CERAD-NAB) vari-
ables; CCR = correct classifi cation rate; AUC = area under the curve. The sensitivity, specifi city, CCR, and AUC in the validation sample are based on appli-
cation of score formulae derived from the training data. 
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(T 2 –T 1 ) is superior to the diagnostic accuracy of T 1 informa-
tion alone, linear combinations of these data were calculated 
for the Chandler and PCA-LR global scores. These values 
were compared with scores from the logistic regression with 
backward elimination (exclusion criterion:  p = .10, inclusion 
criterion:  p = .05) based on all 10  z -transformed CERAD-
NAB variables at timepoints T 1 and T 2 . 
 Statements of signifi cance refer to comparison-wise error 
rates and should be interpreted in a descriptive sense. 
 RESULTS 
 Cross-validation 
 The results of the cross-validation analyses are shown in 
 Table 4 . Because the diagnostic discriminabilities of scores 
in the validation and cross-validation samples were compa-
rable, and to generate a single set of total score formulae, all 
ensuing analyses were conducted on the entire dataset. 
 Cross-sectional Sample (cf.  Table 1 ) 
 The mean uncorrected baseline Chandler total score of the 
NC group was 81.3  (SD = 8.4; range = 53–99), and of the 
AD patients was 56.3 ( SD = 10.0; range = 33–83). The mean 
adjusted Chandler total score for the NC group was 95.4 ( SD = 
7.3; range = 63.5–114.1), higher than that of the AD patients 
(mean = 73.0;  SD = 9.4; range = 47.1–100.9) ( t [494.3] = 
40.9,  p < .001, two-tailed), and the cutoff score was 85.11. 
The formula for the demographic correction was: Chandler 
raw total score – (- 0.391*age + 0.886*education + 
4.447*gender), where gender is coded as man = 0, woman = 
1. This adjusted Chandler total score was highly correlated 
with the adjusted American version ( r = 0.997). 
 The PCA-LR global CERAD-NAB score was based on a 
PCA and logistic regression.  Table 5 contains the factor load-
ings resulting from the PCA of all CERAD-NAB subtest per-
formance of the NC group at T 1 . Factor 1 represents “verbal 
memory,” factor 2 “nonverbal memory,” and factor 3 “non-
memory functions.” The logistic regression of the raw PCA 
factor loadings resulted in the following PCA-LR raw score: = 
4.355 + 2.23*factor1 + 0.466*factor3. The PCA-LR raw scores 
were transformed with t_PCA-LR score = sign(PCA-LR raw score) 
* abs(PCA-LR raw score) 1.15 , with sign(x) = 1 for x  ≥ 0 and = −1 
for x < 0 in preparation for the adjustments for linear and qua-
dratic effects of the demographic variables. The corrected PCA-
LR global  Z score was:  Z _PCA-LR score = [t_PCA-LR score 
– (4.779 + 0.00701*age + 0.05718*education - 0.00246*(age - 
68.68) 2 - 0.02592*(education - 12.47) 2 )] / 3.204. The NC data 
were then linearly transformed to a mean of 100 and  SD of 15 
(range = 51.65–144.04). The mean PCA-LR score for the AD 
patients (mean = 60.34;  SD = 15.75; range = 17.2–109.85) was 
lower than that of the NC participants ( t [1450] = 42.7;  p < .001, 
two-tailed), and the resulting cutoff score was 80.13. 
 The numerical values for the Chandler and PCA-LR 
scores cannot be directly compared because they underwent 
different transformations. 
 The logistic regression analysis resulted in a model con-
taining all 10  z -transformed CERAD-NAB variables which 
provided the best possible discrimination between groups: 
4.961 + (.704*animal fl uency) + (.199*BNT) + (.719*word 
list – total) + (.293* word list – intrusions) + (.459*fi gures – 
copy) + (1.626 word list – delayed recall) – (.408*word 
list – savings) + (.295*word list – recognition) – (.679*fi gures – 
delayed recall) + (1.437*fi gures – savings). 
 To estimate the ability of the global scores to discriminate 
between NC and AD participants, ROC curves were gener-
ated for each global score. The sensitivity and specifi city, as 
well as the CCR of each global score were calculated from 
these ROC curves (see  Table 6 ). Comparisons of the areas 
under the ROC curve revealed that the LR score showed 
trends to discriminate better than the PCA-LR score ( Z = 1.96; 
 p = .05) and the Chandler score ( Z = 1.80;  p = .07). The 
Chandler and PCA-LR scores performed comparably 
( Z = 0.77;  p = .44). The distributions of the Chandler and PCA-
LR scores for NC and AD participants with corresponding 
 Table 5.  Factor loadings of the German CERAD-NAB variables resulting from a principal component analysis (PCA; 
3-factor solution) of healthy aged participants’ performance ( N = 1,100) 
 CERAD variable  Factor 1  Factor 2  Factor 3 
 Animal Fluency  0.115  0.020  0.487 
 Boston Naming Test  0.109  0.078  0.344 
 Word List – Total  0.225  −0.110  0.112 
 Word List – Intrusions a  0.129  −0.130  −0.261 
 Figures – Copy  0.054  0.102  0.543 
 Word List – Delayed Recall  0.290  −0.219  0.036 
 Word List – Savings b  0.228  −0.209  −0.156 
 Word List – Recognition  0.202  −0.169  0.026 
 Figures – Delayed Recall  0.191  0.475  −0.060 
 Figures – Savings c  0.178  0.450  −0.289 
 Note.  CERAD-NAB = Consortium to Establish a Registry on Alzheimer’s Disease-Neuropsychological Assessment Battery. 
 
a
 Number of words provided during the three learning trials and the Word List – Delayed Recall that were not on the Word List. 
 
b
 Proportion of correctly recalled words during the Word List - Delayed Recall compared to the Word List learning trial 3. 
 
c
 Proportion of correctly drawn fi gures during Figures - Delayed Recall compared to Figures - Copy. 
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cut-off scores are shown in  Figure 1a,b . These fi gures illustrate 
the excellent diagnostic discriminabilities of the Chandler 
and PCA-LR scores, as well as the number of false 
classifi cations associated with other, suboptimal, cut-off scores. 
 Longitudinal Subsample (cf.  Table 2 ) 
 Baseline 
 At T 1 , the longitudinal subsample of NC participants had 
higher Chandler scores (mean = 95.42;  SD = 6.95; range = 
73.61–113.7) and PCA-LR scores (mean = 99.95;  SD = 
14.4; range = 51.65–134.74) than the AD patients (Chandler 
score: mean = 74.27;  SD = 9.65; range = 47.11–100.91; 
 t [220.1] = 26.1;  p < .001 , two-tailed; PCA-LR score: mean = 
63.21;  SD = 15.81; range = 28.19–109.85;  t [687] = 27.9; 
p < .001 , two-tailed). The area under the ROC curve of the 
Chandler score did not signifi cantly differ from the area un-
der the ROC curve of the PCA-LR score ( Z = 0.23;  p = .82) 
or the LR score ( Z = 1.18;  p = .24), and the areas under the 
ROC curves of the PCA-LR and LR scores also did not sig-
nifi cantly differ ( Z = 1.07;  p = .28) (see  Table 6 ). 
 Follow-up 
 At T 2 , the NC participants still had a greater Chandler score 
(mean = 98.01,  SD = 6.31) and PCA-LR score (mean = 105.26, 
 SD = 13.76) compared with the AD patients (Chandler 
score: mean = 73.09;  SD = 11.64;  t [195.3] = 26.31;  p < .001; 
PCA-LR score: mean = 60.45;  SD = 18.75;  t [222.4] = 28.39; 
 p < .001), as expected. 
 The LR analysis resulted in a model containing fi ve 
z -transformed CERAD-NAB variables which provided the 
best possible discrimination between groups: 3.767 + (.908*
animal fl uency) – (1.219*word list – total) + (0.603*word 
list – delayed recall) + (.581*word list – recognition) + 
(.731*fi gures – delayed recall). 
 The Chandler and PCA-LR scores demonstrated similar 
discriminatory abilities ( Z = 0.44;  p = .66), as did the LR and 
Chandler scores ( Z = 1.02;  p = .31) as well as LR and PCA-
LR scores ( Z = 0.57;  p = .57). In this subsample, the optimal 
cut-off score for the Chandler score was 85.89 at T 1 and 88.1 
at T 2 , for the PCA-LR score 81.3 at T 1 and 84.82 at T 2 (see 
 Table 6 ). 
 Longitudinal analyses 
 Difference scores (T 2 –T 1 ) were calculated for the Chandler 
and PCA-LR and standardized to a mean of 0 and a  SD of 1 
in the NC sample. Both difference scores for the AD patients 
were signifi cantly different from zero (Chandler score: mean = 
−2.62;  SD = 1.63; range = −6.33–2.16;  t [203.7] = 19.42; 
 p < .001; PCA-LR score: mean = −2.19;  SD = 1.21; range = 
−5.07–1.63;  t [238] = 21.06;  p < .001), indicating a signifi -
cant decline in CERAD-NAB performance over time. The 
sensitivities, specifi cities and CCRs for the Chandler difference 
score were 80.6, 87.8 and 84.2 (AUC = 0.91), respectively, 
and the corresponding values for the PCA-LR difference 
score were 85.5, 85.1 and 85.3 (AUC = 0.922), respectively. 
The LR difference score based on the  z -transformed differ-
ences in  Z score between T 2 and T 1 and following a jackknife 
procedure demonstrated a sensitivity of 85.5, a specifi city of 
90.3 and a CCR of 87.9 (AUC = 0.934). All three measures 
did not signifi cantly differ with respect to their abilities 
to discriminate NC from AD participants’ longitudinal 
performance (AUC comparisons; Chandler  vs. PCA-LR 
score:  Z = 0.79; Chandler  vs. LR:  Z = 1.60; PCA-LR  vs. 
LR:  Z = 0.95). 
 Table 6.  Comparisons of the discriminatory diagnostic characteristics of the Chandler score, PCA-LR score, and LR 
score in the cross-sectional (T 1 ) and longitudinal (T 1 and T 2 ) samples 
  Chandler score  PCA-LR score  LR score 
 Cross-sectional sample (T 1 ) 
 Sensitivity  91.2  91.2  91.2 
 Specifi city  91.6  90.4  92.0 
 CCR  91.4  90.8  91.6 
 AUC  .968  .968 *  .976 
 Longitudinal sample (T 1 ) 
 Sensitivity  89.1  90.3  88.5 
 Specifi city  92.0  89.3  93.1 
 CCR  90.6  89.8  90.8 
 AUC  .960  .962  .969 
 Longitudinal sample (T 2 ) 
 Sensitivity  88.5  92.7  90.3 
 Specifi city  93.1  91.6  93.3 
 CCR  90.8  92.2  91.8 
 AUC  .967  .971  .974 
 Note.  PCA-LR = logistic regression on principal components analysis scores; T 1 = baseline; T 2 = follow-up; CCR = correct classifi cation 
rate; AUC = area under the curve; LR = logistic regression on demographically corrected (CERAD-NAB) variables, results after jack-
knife validation. 
 * Score differs from LR score ( p = .05). 
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 Combination of cross-sectional and longitudinal 
information 
 The results of the binary logistic regression for both combi-
nations [T 1 and T 2 as well as T 1 and difference scores (T 2 – T 1 )] 
for each global CERAD-NAB score are shown in  Table 7 . 
Both sets of scores were comparable in their ability to dis-
criminate NC from AD participants according to compari-
sons of the corresponding areas under the curves (all  Z < 
1.49). While both combinations of PCA-LR scores demon-
strated a higher diagnostic accuracy than PCA-LR scores 
based on T 1 alone (n.b. areas under the curve identical for 
 Fig. 1.  Distribution of (a) Chandler and (b) logistic regression on principal components analysis (PCA-LR) scores in 
healthy elderly individuals (NC) and patients with Alzheimer’s disease (AD) at baseline (T 1 ). Each optimal cutoff score 
classifi es individuals with higher scores as “healthy” and those with lower scores as “demented”. 
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both PCA-LR combination scores;  Z = 2.27,  p = .02), there 
was only a trend for the Chandler combination scores to out-
perform the Chandler score for T 1 (n.b. areas under the curve 
identical for both Chandler combination scores;  Z = 1.88, 
 p = .06), and the already excellent discriminatory power of 
the LR score at baseline did not improve when information 
from T 1 and T 2 were combined ( Z = 1.51,  p = 0.13). 
 DISCUSSION 
 All global CERAD-NAB scores examined here demon-
strated a comparably good ability to correctly classify NC 
participants and very early AD patients. Moreover, the con-
sistency of the total score performance measures in the 
cross-validation analyses indicate that these measures are 
highly stable. The logistic regression represents an ideal 
method for diagnostic discrimination at the group level, and 
the supplementary jackknife procedure optimizes logistic 
regression scores for future samples. The present analyses, 
in which global scores were stringently compared with the 
logistic regression with jackknife procedure, showed that the 
Chandler score and the PCA-LR score both have excellent 
diagnostic discriminability for NC and early AD (we should 
note that the numerical values for the Chandler and PCA-LR 
scores cannot be directly compared because of the different 
methods of derivation and scalings). However, the relative 
ease of calculating the Chandler et al. score makes it a prac-
tical choice for the assessment of early Alzheimer’s disease 
patients with the German CERAD-NAB. 
 The CCRs were most likely affected by several competing 
factors. With respect to the change scores, stringent statis-
tical analyses were used because the test–retest interval of 
the NC participants was nearly double that of the AD pa-
tients, who most likely would have shown an even more pro-
nounced cognitive decline with an equally long test–retest 
interval. Thus, the relatively high CCRs between 84.2% and 
87.9% most likely underestimate the potential of these 
scores to correctly classify individuals on the basis of their 
change in cognitive performance over time and thus also the 
constructed combination scores. Similar to our global scores, 
Zehnder et al. ( 2007 ) reported that individual CERAD-NAB 
subtest baseline and change scores both showed excellent 
diagnostic discriminability for NC and AD in groups who 
had the same test–retest intervals as the present study. More-
over, 78% of AD patients with follow-up testing had received 
acetylcholine-esterase inhibitor treatment between baseline 
and follow-up, which may also have weakened differences 
between the CERAD total scores of NC and AD participants. 
It would be interesting for further studies to quantify the po-
tential effects of such treatments on longitudinal CERAD-
NAB total score performance. AD patients available for 
follow-up also tended to be younger, better educated, and 
have higher MMSE scores than AD patients who were not 
followed-up, factors presumably associated with higher 
CERAD-NAB scores and a decreased CCR. However, an 
additional factor may have led to an overestimation of the 
CCR: CERAD-NAB scores were available to clinicians 
during the diagnostic process. This partial circularity, which 
affected all total scores, most likely artifi cially increased 
their CCRs. 
 The combined baseline and longitudinal PCA-LR scores 
provided signifi cantly greater diagnostic discriminability 
compared with baseline PCA-LR data alone, whereby com-
bined Chandler score information showed a trend to outper-
form corresponding baseline data. These fi ndings suggest 
that the consideration of information from two testing ses-
sions can be diagnostically relevant, especially in the early 
stages of a dementing illness or in cases where uncertainties 
surround the initial diagnosis (e.g., initially good test per-
formance combined with caregiver report or clinical signs 
of impairments in activities of daily living). Indeed, the re-
sults of a recent study (Rosetti, Cullum, Hynan, & Lacritz, 
 2010 ) support the utility of the CERAD total score to 
measure the progression of global neuropsychological im-
pairment in AD. 
 Because also the Chandler total score was developed from 
NC data, it may additionally prove useful in discriminating 
NC individuals from those with other forms of dementia. 
Aebi ( 2002 ) demonstrated that 7 of the 10 CERAD-NAB 
variables discriminated NC from patients with AD, vascular 
dementia and mixed dementia with an accuracy between 81 
and 86%. Moreover, a total score based on a newly devel-
oped, extended version of the German CERAD-NAB 
(“plus”) battery which includes phonemic fl uency (S-words; 
Thurstone,  1938 ) and the TMT (Army Individual Test Bat-
tery,  1944 ) may prove especially useful in discriminating 
NC individuals from patients with subcortical forms of 
dementia. 
 Table 7.  Discriminatory diagnostic characteristics of the Chandler score, PCA-LR score, and LR score for the 
combined cross-sectional and longitudinal data 
 
 Chandler score 
T 1 & T2 
 Chandler score 
T 1 & difference 
 PCA-LR score 
T 1 & T2 
 PCA-LR score 
T 1 & difference 
 LR score 
 z -scores T 1 & T2 
 Sensitivity  89.1  89.1  90.3  90.9  94.5 
 Specifi city  93.1  93.3  92.0  91.8  93.5 
 CCR  91.1  91.2  91.2  91.4  94.0 
 AUC  .974  .974  .978  .978  .979 
 Note.  PCA-LR = logistic regression on principal components analysis scores; T 1 = baseline; T 2 = follow-up; difference = adjusted differ-
ence score (T 2 – T 1 ); CCR = correct classifi cation rate; AUC = area under the curve; LR = logistic regression on demographically cor-
rected (CERAD-NAB) variables, results after jackknife validation. 
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 The higher diagnostic discriminability (NC  vs. AD) of the 
total score in Chandler et al.’s ( 2005 ) population (sensitivity 
93.7% / specifi city 92.6%  vs. 92.0% / 89.1% in the present 
sample) may refl ect differences in demographic correction 
formulae and the more advanced stage of AD in Chandler 
et al.’s population. When the original American demo-
graphic correction formula was applied to our sample, mean 
corrected CERAD total scores of our AD patients (71.6;  SD = 
9.3) were more comparable to those of Chandler et al.’s MCI 
sample (76.9;  SD = 8.9) than their AD sample (60.2;  SD = 
11.9). These fi ndings highlight the challenge of differenti-
ating patients with (amnestic) MCI from those in a very 
early stage of dementia (Winblad et al.,  2004 ). This differen-
tiation will depend in part on assessing complex instrumen-
tal activities in daily living as precisely as possible, although 
it remains unclear what these activities are and how they can 
be discriminated from activities of daily living. This is an 
important topic for further investigation, especially because 
patients with a minimal degree of symptomatology would be 
expected to profi t from a suffi ciently safe and tolerable treat-
ment to delay the progression of the disease, for example, 
immunization therapy (Grimmer, Perneczky, & Kurz,  2008 ). 
For this reason, and in light of recent developments in amy-
loid ß research, the early diagnosis of AD is of central im-
portance (Forsberg et al.,  2008 ; Pike et al.,  2007 ). The 
CERAD neuropsychological assessment battery appears to 
be an excellent tool for this purpose. 
 Complex cognitive profi les composed of a large number 
of individual test scores can be a cumbersome form of 
communicating an individual’s cognitive status, espe-
cially in intervention or longitudinal studies where indi-
vidual scores can show independent and in some cases 
divergent patterns over time. In many cases, instruments 
such as the ADAS-Cog have been used in addition to the 
MMSE (Brodaty, Corey-Bloom, Potocnik, Truyen, Gold, & 
Damaraju,  2005 ; Rogers, Farlow, Doody, Mohs, & Friedhoff, 
 1998 ; Seltzer et al.,  2004 ; Tariot, Solomon, Morris, Kershaw, 
Lilienfeld, & Ding,  2000 ). The CERAD-NAB has the 
advantage over the ADAS-Cog and MMSE of measuring 
both delayed recall and recognition from episodic memory, 
functions critically impaired in AD. The CERAD total 
score based on demographically corrected raw scores rep-
resents a practical alternative tool to assess global cogni-
tive functioning. During repeated testing with the validated 
CERAD-NAB, this score allows for easily communicable 
conclusions to be made about the course of cognitive func-
tioning and, therefore, appears especially suited to inter-
vention studies, for example, to assess the potential 
modifi cation of disease progression with different kinds of 
pharmacotherapy. 
 For the German version of the CERAD-NAB, Chandler 
et al.’s ( 2005 ) method of calculating a total score adjusted 
for the infl uences of demographic variables can be recom-
mended. This score is much simpler to calculate than the 
global CERAD-NAB score based on a principal component 
analysis (i.e., PCA-LR score) and provides an effective 
global measure of cognitive functioning. 
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